Upadacitinib Delivers Rapid Response in Ulcerative Colitis :

Serious and severe adverse events, as well as higher rates of discontinuation due to treatment-related adverse events, were more common in the placebo group.

Related Keywords

California , United States , San Diego , Milan , Lombardia , Italy , Ann Arbor , Michigan , Silvio Danese , Peter Higgins , Siddharth Singh , University Of California , York University Langone Health , Genentech , Research Center , University Of Michigan , Pfizer , American College Of Gastroenterology , Astrazeneca , Humanitas Clinical , American College , New York University Langone Health , Inflammatory Bowel Disease , Nflammatory Bowel Disease Ibd , Bd , Colitis , Ulcerative Colitis , Neoadjuvant , Remission , Clinical Research , Clinical Trials , Linical Studies , Biologic Therapy , Cancer , Alignant Neoplasia , Arcinoma , Generics , Generic Drug , Eneric Medication , Neutropenia , Activism , Activist , Adverse Effects , Side Effects , , Cardiovascular Disease , Vd Cardiovascular Disease , Cv , Ardiovascular ,